Factor Product Utilization and Health Outcomes in Patients With Hemophilia
Factor Product Utilization and Health Outcomes in Patients With Hemophilia A and B in Canada: An Observational Study of Real-world Outcomes
Sponsor: Biogen
This observational or N/A phase trial investigates Hemophilia A, Congenital and Hemophilia B, Congenital and is currently completed. Biogen leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2021 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Jul 2019 — Nov 2020 [monthly]
Recruiting
-
Jun 2018 — Jul 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Nov 2017 [monthly]
Recruiting NA
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
- University of British Columbia
For direct contact, visit the study record on ClinicalTrials.gov .